Palomar projects $10-15 mil. in Epilaser sales for remainder of 1996.
This article was originally published in The Gray Sheet
PALOMAR EPILASER WILL GENERATE $10-15 MIL. IN REVENUE by the end of calendar 1996, Chairman and CEO Steven Georgiev said at a July 15 investor conference held in New York City. FDA cleared the firm's 510(k) on July 12 for a broad range of dermatological applications such as the removal of pigmented lesions, tattoos, skin lesions and birth marks.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.